Clinical Pathology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
Clinical Oncology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
Int J Lab Hematol. 2024 Feb;46(1):107-112. doi: 10.1111/ijlh.14186. Epub 2023 Oct 10.
Chronic lymphocytic leukemia (CLL) is characterized by a very heterogeneous clinical outcome. Thus, a plethora of prognostic factors and systems has been identified to place patients into different risk categories and to guide therapy decisions. The classic clinical staging models by Rai and Binet have been the cornerstone of patient management for several years. The greater insight into the molecular biology of CLL facilitated the advent of prognostic genetic biomarkers that are expected to impact clinical practice soon in the future. Therefore, we aimed to investigate the expression of long non-coding RNA (lncRNA) CRNDE in patients with CLL, and to analyze its relationship with the clinicopathological parameters of CLL.
In this study, 40 untreated CLL patients and 30 age- and gender-matched controls were enrolled. The analysis of lncRNA CRNDE expression was determined using reverse transcription-quantitative polymerase chain reaction technique.
Our result confirmed the downregulated expression of LncRNA CRNDE in CLL patients compared to controls (p < 0.001). The low expression of CRNDE was significantly associated with poor prognostic markers including advanced stage of CLL, high levels of serum beta-2 microglobulin and lactic dehydrogenase, and the presence of del17p (p = 0.029, p = 0.013, p = 0.003, p = 0.028; respectively).
Our study demonstrated that LncRNA CRNDE is significantly downregulated and associated with poor prognostic markers in CLL. It provides a rationale to assess its biological and prognostic impact in CLL.
慢性淋巴细胞白血病（CLL）的临床结局非常多样化。因此，已经确定了大量的预后因素和系统，将患者分为不同的风险类别，并指导治疗决策。Rai 和 Binet 的经典临床分期模型多年来一直是患者管理的基石。对 CLL 分子生物学的更深入了解促进了预后遗传生物标志物的出现，预计这些标志物将在不久的将来对临床实践产生影响。因此，我们旨在研究长链非编码 RNA（lncRNA）CRNDE 在 CLL 患者中的表达，并分析其与 CLL 临床病理参数的关系。
本研究纳入了 40 例未经治疗的 CLL 患者和 30 名年龄和性别匹配的对照者。采用逆转录定量聚合酶链反应技术分析 lncRNA CRNDE 表达。
我们的结果证实，与对照者相比，CLL 患者的 LncRNA CRNDE 表达下调（p<0.001）。CRNDE 的低表达与预后不良标志物显著相关，包括 CLL 的晚期阶段、血清β2 微球蛋白和乳酸脱氢酶水平升高以及 del17p 的存在（p=0.029、p=0.013、p=0.003、p=0.028；分别）。
我们的研究表明，LncRNA CRNDE 在 CLL 中显著下调，并与预后不良标志物相关。它为评估其在 CLL 中的生物学和预后影响提供了依据。
